Headquarters: San Diego, CA, USA
Founded: 2021
Focus: TFEB activators for neurodegeneration
Status: Private
Appvian Therapeutics is a US-based biotechnology company developing small molecule therapeutics that target the TFEB (Transcription Factor EB) pathway for the treatment of neurodegenerative diseases. The company's lead program, ATL-02, is a TFEB activator being developed for Parkinson's disease, with a focus on patients with ATP13A2 and other lysosomal genetic risk factors.
| Program |
Indication |
Stage |
Mechanism |
| ATL-02 |
Parkinson's Disease |
Preclinical |
TFEB activator |
| ATL-03 |
Alzheimer's Disease |
Discovery |
TFEB activator |
| ATL-04 |
Lysosomal Storage Disorders |
Discovery |
TFEB activator |
TFEB is the master regulator of lysosomal biogenesis and autophagy:
- Controls expression of lysosomal enzymes and autophagy genes
- Promotes clearance of protein aggregates
- Enhances mitochondrial quality control (mitophagy)
- Activity is impaired in neurodegenerative diseases
In PD, TFEB nuclear localization and activity are suppressed:
- mTORC1 hyperactivity sequesters TFEB in cytoplasm
- Lysosomal dysfunction impairs TFEB signaling
- Alpha-synuclein accumulation further inhibits TFEB
Activating TFEB can compensate for multiple upstream defects:
- GBA mutations: Enhanced lysosomal biogenesis
- ATP13A2 deficiency: Restored lysosomal function
- LRRK2 mutations: Improved trafficking
ATL-02 is a selective TFEB activator:
- mTORC1 inhibition: Partial inhibition releases TFEB
- Nuclear translocation: TFEB enters nucleus
- Gene activation: Enhances lysosomal biogenesis genes
- Autophagy enhancement: Increases alpha-synuclein clearance
Appvian's platform enables:
- Structure-based design of TFEB modulators
- Optimization for brain penetration
- Selectivity over related TFE3/S1TF pathways
- Oral bioavailability
The company uses:
- Primary neurons from PD patient iPSCs
- Mouse models with lysosomal defects
- Biomarker development for clinical translation
¶ Competitive Landscape
| Company |
Approach |
Stage |
| AtlasX Bio |
TFEB activator (ATL-1001) |
Phase I planned |
| Lyterian |
Autophagy/TFEB modulator |
Preclinical |
| Gain Therapeutics |
GCase chaperone |
Phase 1b |